Venous thrombotic events in severe and critically COVID-19 patients despite high dose prophylactic low-molecular-weight heparin | Zendy

Chantal Visser | Zendy; Reinier A. Sprenger | Zendy; Hans J. van den Bout | Zendy; Dirk P. Boer | Zendy; Rachida el Moussaoui | Zendy; Jan G. den Hollander | Zendy

Open Access

Venous thrombotic events in severe and critically COVID-19 patients despite high dose prophylactic low-molecular-weight heparin

Author(s) -

Chantal Visser,

Reinier A. Sprenger,

Hans J. van den Bout,

Dirk P. Boer,

Rachida el Moussaoui,

Jan G. den Hollander

Publication year - 2020

Publication title -

thrombosis update

Language(s) - English

Resource type - Journals

ISSN - 2666-5727

DOI - 10.1016/j.tru.2020.100006

Subject(s) - medicine , low molecular weight heparin , heparin , pneumonia , intensive care unit , venous thrombosis , thrombosis , prophylactic treatment , covid-19 , pulmonary embolism , critically ill , intensive care medicine , incidence (geometry) , disease , physics , infectious disease (medical specialty) , optics

Hypercoagulation is one of the most distinct prognostic factors of patients with COVID-19 and has been associated with arterial thrombosis and other venous thrombotic events (VTE). Bleeding complications are far less encountered. The International Society on Thrombosis and Haemostasis (ISTH) guidance advises giving prophylactic low-molecular-weight heparin (LMWH) to prevent these events, although there is evidence that the incidence remains high despite using prophylactic LMWH. We describe three cases of COVID-19 pneumonia that were admitted to our intensive care unit (ICU) and developed acute pulmonary embolisms (APE) despite high dosage prophylactic LMWH. These cases raise concerns about using prophylactic LMWH instead of therapeutic anticoagulation in severe and critically COVID-19 patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research